Document Detail


Prediction model for adult height of small for gestational age children at the start of growth hormone treatment.
MedLine Citation:
PMID:  18000093     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONTEXT: GH treatment is approved for short children born small for gestational age (SGA). The optimal dose is not yet established. OBJECTIVE: Our objective was to develop a model for prediction of height at the onset of puberty and of adult height (AH). DESIGN AND SETTING: Two GH studies were performed in short SGA children. PATIENTS/INTERVENTION: A total of 150 SGA children with height sd scores (SDS) less than -2, age 3 yr or older, no signs of catch-up growth, available height at the onset of puberty, and at least 1 yr of GH treatment before the onset of puberty were studied. In one study, patients were randomly assigned to either 0.033 or 0.067 mg/kg x d; in the other study all received 0.033 mg/kg x d. In 71 children, AH was reached. MAIN OUTCOME MEASURES: Height SDS at the onset of puberty and AH SDS were calculated. RESULTS: Determinants positively related to height SDS at the onset of puberty were: height SDS at the start; target height SDS; and GH dose, whereas age at the start and female gender were negatively related. Positively related to AH SDS were: height SDS and chronological age--bone age at the start; target height SDS; and GH dose, whereas serum IGF binding protein (IGFBP)-3 SDS at the start was negatively related. There was a significant interaction between GH dose and IGFBP-3 SDS, indicating a smaller GH dose effect for higher levels of IGFBP-3. The final model explained 57% of the variance in height SDS at the onset of puberty and 41% of AH SDS. CONCLUSIONS: The prediction model for height SDS at the onset of puberty and AH SDS of short SGA children treated with GH provides useful information about the expected long-term growth. Because GH dosage is one of the determinants, the model aids in determining the optimal GH dose for each child.
Authors:
Maria A J de Ridder; Theo Stijnen; Anita C S Hokken-Koelega
Related Documents :
9916863 - Circulating leptin level and growth hormone response to stimulation tests in obese and ...
8200933 - Reduced concentration of serum growth hormone-binding protein in children with idiopath...
2937153 - First diagnosis of severe mental handicap: characteristics of unsatisfactory encounters...
Publication Detail:
Type:  Journal Article     Date:  2007-11-13
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  93     ISSN:  0021-972X     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-02-08     Completed Date:  2008-04-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  477-83     Citation Subset:  AIM; IM    
Affiliation:
Dutch Growth Foundation, P.O. Box 23068, 3001 KB Rotterdam, The Netherlands. m.deridder@erasmusmc.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Body Height / drug effects,  physiology*
Child
Child, Preschool
Female
Hormone Replacement Therapy / methods*
Human Growth Hormone / therapeutic use*
Humans
Infant, Newborn
Infant, Small for Gestational Age / metabolism,  physiology*
Insulin-Like Growth Factor Binding Protein 3 / blood
Insulin-Like Growth Factor I / metabolism
Linear Models
Male
Models, Biological*
Chemical
Reg. No./Substance:
0/Insulin-Like Growth Factor Binding Protein 3; 12629-01-5/Human Growth Hormone; 67763-96-6/Insulin-Like Growth Factor I

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Height velocity targets from the national cooperative growth study for first-year growth hormone res...
Next Document:  Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial.